Trials / Available
AvailableNCT06034886
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
Intermediate-Size Patient Population Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Detailed description
This is an Intermediate-Size Patient Population Expanded Access Protocol designed to provide treatment use of troriluzole to patients with spinocerebellar ataxia (SCA) who are considered to be eligible in the clinical judgement of the Investigator/treating physician. The population includes both troriluzole naive patients and patients participating in previous clinical trials with troriluzole (BHV4157-201 and BHV4157-206) who have a confirmed diagnosis of spinocerebellar ataxia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Troriluzole | BHV-4157 140mg, 200mg or 280mg once daily by mouth. |
Timeline
- First posted
- 2023-09-13
- Last updated
- 2026-01-09
Source: ClinicalTrials.gov record NCT06034886. Inclusion in this directory is not an endorsement.